Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
Konstantinos Liapis & Ioannis Kotsianidis, on behalf of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes.
Popular Content
Cookies
We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.
Further information can be found in our privacy policy.
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.